ITB-MED

ITB-MED is a leading biotechnology research company dedicated to the advancement of innovative therapies, particularly in the fields of transplantation and autoimmunity. ITB-MED is focused on the development of TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody, for multiple indications. The company's commitment extends to conducting comprehensive worldwide clinical trials to explore the full potential of TCD601. ITB-MED's primary address is located at 110 E 59th St, 28, New York, 10022, US, with additional facilities at Hagaplan 4, Stockholm, 11368, SE.

ITB-MED is actively engaged in investigating further preclinical therapies, aiming to broaden the scope of its novel immune-modulating approaches. By leveraging cutting-edge research and development, ITB-MED strives to make significant contributions to the medical community and improve patient outcomes. The company is driven by a vision of transforming healthcare through innovative biotechnological solutions.

ITB-MED's dedication to pioneering research and clinical development positions it as a key player in the biotechnology sector. The company's ongoing efforts are geared toward expanding its therapeutic pipeline and enhancing its impact on global healthcare. We invite the manager of ITB-MED to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and commercial development.